Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Castration-resistant Prostate Cancer|Metastatic Breast Cancer|Uterine Leiomyoma
Interventions: DRUG: LFA102
Sponsor: Novartis Pharmaceuticals